BioCentury
ARTICLE | Strategy

Home run in extra innings

April 10, 2006 7:00 AM UTC

Rinat Neuroscience Corp.'s four and a half-year history is a textbook example of how old-school biotechs create value - use a deep biology approach to produce protein therapeutics with first- or best-in-class mechanisms in large indications - a strategy that reveals the company's roots in Genentech Inc.

Indeed, that selling proposition had a host of pharma companies seeking to buy the biotech play. The feeding frenzy ended last week, as Rinat announced that it's being acquired by Pfizer Inc. ...